Bangalore, India -- (SBWire) -- 12/26/2017 --The nomenclature for such devices includes transcatheter heart valve replacement (THVR) and percutaneous heart valve replacement. In this instance, 'percutaneous' is used interchangeably with 'transcatheter'. For the sake of this report, these devices will be referred to as transcatheter heart valve replacement devices. The industry standard is to define these products further by denoting the specific heart valve for which the device is indicated. Examples of this would be transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR) devices and transcatheter pulmonary valve replacement (TPVR) devices.
In a transcatheter heart valve replacement procedure, a collapsible replacement valve is delivered to the damaged valve via a balloon catheter. The balloon catheter then inflates to expand the replacement within the old valve, pushing the old valve leaflets out of the way and allowing the replacement valve to regulate blood flow. The balloon catheter is then deflated and removed.
The primary method for treating heart valve conditions is through open surgery to place a replacement valve. Biological tissue valves can be allografts (provided by deceased donors), xenografts (bovine or porcine valves) or autografts (using the patient's own pulmonary valve, which in turn, needs to be replaced).
Tissue valves have been gaining popularity over the alternative mechanical valves because tissue valves are much more biocompatible and do not require lifelong treatment with anti-coagulant medication. However, mechanical valves are more durable and are designed to last for 20-30 years, whereas bioprosthetic valves last 10-15 years. Some patients with heart valve problems are poor candidates for valve replacement surgery because they may be too ill to undergo such an invasive procedure. Therefore, there is a great deal of interest in the development of transcatheter heart valve replacement (THVR) devices.
Spanning over 381 pages "US Market Report for Transcatheter Heart Valve Replacement Machines 2018 - MedCore" report covers Executive Summary, Competitive Analysis, Market Trends, Market Developments, Research Methodology, Disease Overview, Product Portfolio, Transcatheter Heart Valve Replacement Device Market, Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo, Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore, SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica, Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.
For more information Visit at: https://www.drugpipeline.net/idata-research/us-market-report-transcatheter-heart-valve-replacement-machines-2018-medcore
Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare
Related Reports;
US Market Report for Transmyocardial Revascularization Devices 2018 - MedCore - Visit at - https://www.drugpipeline.net/idata-research/us-market-report-transmyocardial-revascularization-devices-2018-medcore
US Market Report for Ventricular Assist Devices 2018 - MedCore - Visit at - https://www.drugpipeline.net/idata-research/us-market-report-ventricular-assist-devices-2018-medcore
About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.
US Market Report for Transcatheter Heart Valve Replacement Machines 2018; New Report Launched
DrugPipeline.net has announced the addition of “US Market Report for Transcatheter Heart Valve Replacement Machines 2018 - MedCore” research report to their website www.DrugPipeline.net